Tenmile

Tenmile is an Australian venture capital firm based in Perth, with team members also located in Melbourne, Sydney, and San Francisco. Established in 2022, the firm was founded with an initial capital allocation of $250 million from Tattarang, the private investment group owned by Australian billionaires Andrew and Nicola Forrest. Tenmile's core mission is to bridge the critical gap between groundbreaking scientific research and its translation into scalable, global health solutions, focusing intently on areas of unmet medical need.

What sets Tenmile apart is its unique operational model. Unlike traditional venture capital funds that are constrained by closed-end structures, Tenmile operates with an evergreen seed and expansion capital model. This allows the firm to act with remarkable speed and confidence, providing sustained support to early-stage companies, researchers, and entrepreneurs without the typical obligations to external investors or lending providers. They prioritise a 'founder-first' approach, combining deep sector knowledge with hands-on experience to help transform innovative science into lasting commercial and patient impact.

Tenmile is committed to fostering a thriving Australian health science and technology sector, extending support to ensure local breakthroughs achieve global reach. The firm's investment philosophy is deeply anchored in ethical and sustainable health treatments and technologies, with a specific framework that includes backing female-founded and led health businesses. Their experienced team brings diverse backgrounds in medicine, academia, tech transfer, pharmaceuticals, biotechnology, and investment banking, offering comprehensive insight and extensive networks to navigate complex markets and accelerate growth.

Key leadership at Tenmile includes Dr. Steve Burnell, Managing Director and Chair of the Investment Committee, who brings extensive experience from Roche-Genentech in digital health and precision oncology. John Hartman serves as a member of the Investment Committee and is the Chief Executive Officer of Tattarang and the Minderoo Foundation, overseeing a vast portfolio. Dr. Liz Dallimore, also on the Investment Committee, is the CEO and Managing Director of Argenica Therapeutics, contributing over 20 years of experience in biotechnology and management consulting. The team also includes Aizaz Syed as Senior Portfolio and Investment Manager, Dr. Arjun Balaji as Entrepreneur In Residence, and Emily Casey as Community & Partnerships Lead, all playing crucial roles in identifying and nurturing promising health technology ventures.